UK awards £4million for pharmacogenetic screening research and development:
This article was originally published in Clinica
Executive Summary
The UK's Department of Health today announced six pharmacogenetics research projects that will receive grants totalling £4m ($7.4m). One of the topics being funded from the £50m national genetics strategy is universal pre-surgery screening for predisposition to the potentially fatal malignant hyperthermia, as a reaction to a commonly used general anaesthetic. The other projects are on tests to assess the risk of adverse reactions to drug therapies, including: dosification of anthracyclines (cancer drug), which can cause severe heart damage; patient response to epilepsy drugs and anti-clotting agents; susceptibility to liver injury from penicillin and anti-turberculosis medicines; potential adverse reactions to inflammatory disease treatments.
You may also be interested in...
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.